New NIH Awa d will I itially P ovide Neu oO e App oximately $200,000 th ough Ap il 2027
EDEN PRAIRIE, Mi ., Oct. 08, 2026 (GLOBE NEWSWIRE) — Neu oO e Medical Tech ologies Co po atio (Nasdaq: NMTC) (“Neu oO e” o the “Compa y”), a medical tech ology compa y dedicated to t a sfo mi g the su gical diag osis a d t eatme t of eu ological diso de s, today a ou ced it has e te ed i to a esea ch a d developme t subawa d ag eeme t with Da tmouth to suppo t the adva ceme t of ext-ge e atio eu ot a smitte se si g tech ology.
Resea che s at Da tmouth College, led by Associate P ofesso of E gi ee i g Hui Fa g, have eceived a Natio al I stitutes of Health (NIH) g a t of app oximately $1 millio fo the fi st yea , with additio al fu di g expected du i g the followi g two yea s. The g a t is titled “T a slati g Novel Ca bo Coati g Towa ds I teg ated Sub-Seco d Neu ot a smitte Se so s i Huma s,” which is fu ded by the Natio al I stitute of Neu ological Diso de s a d St oke (NINDS) th ough the NIH BRAIN I itiative. Neu oO e will eceive app oximately $200,000 th ough Ap il 30, 2027, with additio al fu ds expected du i g the followi g two yea s.
The collabo ative effo t b i gs togethe expe tise f om Da tmouth, the VA Medical Ce te , Beth Is ael Deaco ess Medical Ce te , a d Neu oO e to t a slate ece t adva ces i eu ochemical se si g towa d pote tial use i huma s.
The collabo atio seeks to combi e adva ced eu ochemical se si g capabilities with cli ically eleva t eu al i te face tech ologies to p ovide physicia s a d esea che s with ew tools fo mo ito i g b ai activity a d eu ochemical sig ali g i eal time usi g Neu oO e’s sEEG elect odes. The ability to simulta eously measu e elect ical a d eu ochemical activity help adva ce u de sta di g, diag osis, a d t eatme t of eu ological a d psychiat ic diso de s.
“We a e excited to collabo ate with Da tmouth o this NIH-suppo ted i itiative,” said Dave Rosa, CEO of Neu oO e. “This g a t is a othe compelli g example of the ve satility a d pote tial of Neu oO e’s thi -film elect ode tech ology platfo m. While ou tech ology has al eady demo st ated value i eco di g, stimulatio , a d the apeutic applicatio s, we believe its flexible desig a d high-pe fo ma ce cha acte istics c eate oppo tu ities well beyo d those uses.”
Neu oO e Medical Tech ologies Co po atio is a medical tech ology compa y focused o imp ovi g su gical ca e optio s a d outcomes fo patie ts suffe i g f om eu ological diso de s. Neu oO e ma kets a mi imally i vasive a d high-defi itio /high-p ecisio elect ode tech ology platfo m with fou FDA-clea ed p oduct families: Evo® Co tical Elect odes, Evo® sEEG Elect odes, O eRF® Ablatio System (fo b ai ), a d O eRF® T igemi al Ne ve Ablatio System. These solutio s offe the pote tial to educe the umbe of hospitalizatio s a d su gical p ocedu es, lowe costs, a d imp ove patie t outcomes by offe i g diag ostic a d the apeutic fu ctio s. The Compa y is e gaged i esea ch a d developme t fo d ug delive y, basive teb al e ve ablatio a d spi al co d stimulatio p og ams. Fo mo e i fo matio , visit mtc1.com.
This p ess elease may i clude fo wa d-looki g stateme ts withi the mea i g of Sectio 27A of the Secu ities Act of 1933, as ame ded, a d Sectio 21E of the Secu ities Excha ge Act of 1934, as ame ded. Except fo stateme ts of histo ical fact, a y i fo matio co tai ed i this p ess elease may be a fo wa d–looki g stateme t that eflects Neu oO e’s cu e t views about futu e eve ts a d a e subject to k ow a d u k ow isks, u ce tai ties a d othe facto s that may cause ou actual esults, levels of activity, pe fo ma ce o achieveme ts to be mate ially diffe e t f om the i fo matio exp essed o implied by these fo wa d-looki g stateme ts. I some cases, you ca ide tify fo wa d–looki g stateme ts by the wo ds o ph ases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “i te d,” “pla ,” “objective,” “a ticipate,” “believe,” “estimate,” “p edict,” “p oject,” “pote tial,” “ta get,” “seek,” “co template,” “co ti ue,” “focused o ,” “committed to” a d “o goi g,” o the egative of these te ms, o othe compa able te mi ology i te ded to ide tify stateme ts about the futu e. Fo wa d–looki g stateme ts may i clude stateme ts ega di g the pote tial eceipt of fu ds f om the NIH-g a t. Although Neu oO e believes that we have a easo able basis fo each fo wa d-looki g stateme t, we cautio you that these stateme ts a e based o a combi atio of facts a d facto s cu e tly k ow by us a d ou expectatio s of the futu e, about which we ca ot be ce tai . Ou actual futu e esults may be mate ially diffe e t f om what we expect due to facto s la gely outside ou co t ol, ou pa t e ships may ot facilitate the comme cializatio o ma ket accepta ce of ou tech ology; whethe due to supply chai dis uptio s, labo sho tages, isks that ou tech ology will ot pe fo m as expected based o esults of ou p e-cli ical a d cli ical t ials; isks elated to u ce tai ties associated with the Compa y’s capital equi eme ts to achieve its busi ess objectives a d ability to aise additio al fu ds: the isk that we may ot be able to secu e o etai cove age o adequate eimbu seme t fo ou tech ology; u ce tai ties i he e t i the developme t p ocess of ou tech ology; isks elated to cha ges i egulato y equi eme ts o decisio s of egulato y autho ities; that we may ot have accu ately estimated the size a d g owth pote tial of the ma kets fo ou tech ology; isks elated to ou ability to p otect ou i tellectual p ope ty ights; a d othe isks, u ce tai ties a d assumptio s, i cludi g those desc ibed u de the headi g “Risk Facto s” i ou fili gs with the Secu ities a d Excha ge Commissio . These fo wa d–looki g stateme ts speak o ly as of the date of this p ess elease a d Neu oO e u de takes o obligatio to evise o update a y fo wa d–looki g stateme ts fo a y easo , eve if ew i fo matio becomes available i the futu e.
